| scholarly article | Q13442814 |
| P50 | author | Monica M Farley | Q106358785 |
| P2093 | author name string | Sarah W Satola | |
| Jean B Patel | |||
| Karen F Anderson | |||
| P2860 | cites work | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications | Q24646677 |
| Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages | Q30341876 | ||
| Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options | Q32058531 | ||
| Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. | Q33613735 | ||
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis | Q34885043 | ||
| Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia | Q35023343 | ||
| Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 | ||
| Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center | Q35784453 | ||
| A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). | Q36083140 | ||
| Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains | Q36328966 | ||
| Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy | Q36328976 | ||
| The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 | ||
| Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). | Q36898180 | ||
| Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. | Q37058087 | ||
| Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides | Q39465279 | ||
| Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex | Q39882528 | ||
| Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center | Q41387835 | ||
| Historical yearly usage of vancomycin. | Q42743595 | ||
| Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. | Q42752989 | ||
| A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides | Q42912582 | ||
| Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 micrograms per milliliter by automated testing | Q43071735 | ||
| Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals | Q43278332 | ||
| Detection of glycopeptide resistance in Staphylococcus aureus | Q43533645 | ||
| A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital | Q43552304 | ||
| Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. | Q43834620 | ||
| A microdilution plating method for population analysis of antibiotic-resistant staphylococci | Q43835313 | ||
| Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis | Q44380530 | ||
| Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? | Q44863523 | ||
| hGISA: seek and ye shall find | Q45012128 | ||
| Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 | ||
| Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia | Q46130414 | ||
| A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital | Q46802703 | ||
| Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. | Q51785920 | ||
| Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 | ||
| Low-level teicoplanin resistance and heteroresistance to vancomycin. | Q54148202 | ||
| The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan | Q74823194 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| P304 | page(s) | 177-183 | |
| P577 | publication date | 2010-11-03 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method | |
| P478 | volume | 49 |
| Q30455758 | A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin |
| Q37544625 | Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States |
| Q41094106 | Adaptation to vancomycin pressure of multiresistant Staphylococcus capitis NRCS-A involved in neonatal sepsis |
| Q36367474 | Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study |
| Q100395098 | Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) |
| Q36116970 | Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital |
| Q35066896 | Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au |
| Q38425879 | Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus |
| Q35598902 | Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States |
| Q33696380 | Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association. |
| Q36276932 | Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia |
| Q36118613 | First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus |
| Q92320936 | Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India |
| Q42253063 | Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia |
| Q42236835 | Heterogeneous glycopeptide intermediate Staphylococcus epidermidis isolated from prosthetic joint infections |
| Q37168667 | Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence |
| Q93000971 | Mechanisms and clinical relevance of bacterial heteroresistance |
| Q34163608 | Methicillin-resistant Staphylococcus capitis with reduced vancomycin susceptibility causes late-onset sepsis in intensive care neonates |
| Q91861618 | Methods to Evaluate Colistin Heteroresistance in Acinetobacter baumannii |
| Q61455129 | Multidrug-Resistant Bacteria Associated with Cell Phones of Healthcare Professionals in Selected Hospitals in Saudi Arabia |
| Q26822729 | Multidrug-resistant bacteria in solid organ transplant recipients |
| Q93270949 | Niche specialization and spread of Staphylococcus capitis involved in neonatal sepsis |
| Q41877894 | Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates |
| Q36410012 | Phenotypic characterisation of coagulase-negative staphylococci isolated from blood cultures in newborn infants, with a special focus on Staphylococcus capitis |
| Q35273507 | Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin |
| Q36636699 | Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients |
| Q37697213 | Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia. |
| Q58572959 | Rapid Detection of Heterogeneous Vancomycin-Intermediate Based on Matrix-Assisted Laser Desorption Ionization Time-of-Flight: Using a Machine Learning Approach and Unbiased Validation |
| Q35607909 | Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae |
| Q42905367 | Reduced vancomycin susceptibility in porcine ST9 MRSA isolates |
| Q41031199 | Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmatio |
| Q34146127 | Spread of epidemic MRSA-ST5-IV clone encoding PVL as a major cause of community onset staphylococcal infections in Argentinean children |
| Q36457109 | The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia. |
| Q42932594 | Using genomics to standardize population analysis profile-area under the curve ratio for vancomycin-intermediate Staphylococcus aureus |
| Q84922061 | Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients |
| Q61814412 | Vancomycin MIC Distribution among Methicillin-Resistant . Is Reduced Vancomycin Susceptibility Related To MIC Creep? |
| Q35064413 | Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey |
| Q41711192 | Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt |
| Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
| Q38811664 | Vancomycin, teicoplanin, daptomycin, and linezolid MIC creep in methicillin-resistant Staphylococcus aureus is associated with clonality |
Search more.